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Abstract
Background: This study aimed to develop an easy to use prediction model to predict
the risk of having a total of 1 to 2, ≥3, or ≥4 positive axillary lymph nodes (LNs), for
patients with sentinel lymph node (SLN) positive breast cancer.
Methods: Data of 911 SLN positive breast cancer patients were used for model
development. The model was validated externally in an independent population of
180 patients with SLN positive breast cancer.
Results: Final pathology after ALND showed additional positive LN for 259 (28%)
of the patients. A total of 726 (81%) out of 911 patients had a total of 1 to 2
positive nodes, whereas 175 (19%) had ≥3 positive LNs. The model included
three predictors: the tumor size (in mm), the presence of a negative SLN, and
the size of the SLN metastases (in mm). At external validation, the model showed
a good discriminative ability (area under the curve = 0.82; 95% confidence
interval = 0.74‐0.90) and good calibration over the full range of predicted
probabilities.
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Conclusion: This new and validated model predicts the extent of nodal involvement in
node‐positive breast cancer and will be useful for counseling patients regarding their
personalized axillary treatment.
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1 | INTRODUCTION
The axillary treatment of breast cancer has changed significantly
over time. After the implementation of the sentinel lymph node
biopsy (SLNB) procedure, only patients with sentinel lymph node
(SLN) metastases were selected for treatment by a completion
axillary lymph node dissection (ALND). The IBCSG 23‐01 study
showed that a completion ALND could be omitted for patients
with micrometastases.1 Furthermore, the ACOSOG Z0011 trial
showed that for a selected subgroup of patients, a small volume of
disease left behind in the axilla does not compromise the
oncological safety, in terms of recurrence and disease‐free and
overall survival.2 Also, the results of the AMAROS trial, published
in 2014, changed our perspective on axillary treatment showing
that both radiotherapy, as well as surgery, can provide excellent
regional control.3 These studies have had a significant impact on
the management of the axilla.4
It is obvious that the trend is heading towards a less invasive
surgical treatment of the axilla. ALND has lost its importance for
determining the need of adjuvant systemic treatment4,5 and
gradually seems to lose its importance for locoregional control.
However, there remain several subgroups of breast cancer
patients for whom treatment of the axilla may still be necessary.
These include patients who were found to be node positive with
ultrasound‐guided lymph node biopsy (UGLNB). This appears to be
a different group of node‐positive patients with less favorable
disease characteristics and a worse disease‐free and overall
survival as compared with those with SLN positive disease.6,7
Another group may be the patients who are treated with a
mastectomy rather than breast‐conserving surgery (BCS), as
radiotherapy may partially include the axilla when used as
adjuvant treatment after BCS.8
In the last decade, the focus was set on finding patients with SLN
positive breast cancer with a low risk of additional nodal involve-
ment, for whom a completion ALND could be omitted. Several
predictive systems have been developed to help identifying such
patients.9-17 Now that also a low risk of limited nodal involvement is
increasingly accepted to omit further axillary treatment, it is time to
search for the patients at high risk for extensive nodal involvement
who may still benefit from additional treatment of the axilla.
Presently, three predictive models have been proposed, that predict
the risk of having four or more positive axillary lymph nodes
(LNs).18-20 The main purpose of these models is to help decide on the
extent of radiation and/or systemic therapy and whether an
immediate breast reconstruction can be offered to these pa-
tients.18-20 To our knowledge, there is no model, that predicts the
extent of nodal involvement.
The aim of the present study was to develop a tool for predicting
the extent of nodal involvement in node‐positive breast cancer
patients. Such a tool may then be used for counseling in the clinical
decision‐making process, in the present “treat none—unless” era,
regarding the additional axillary treatment strategies.
2 | METHODS
2.1 | Study population
The study population consisted of three consecutively selected
patient groups. The original patient series for model development
were identified from the Netherlands Cancer Registry (NCR) of
the South region of the Netherlands in which 10 hospitals
participated. The dataset included breast cancer patients with
SLN‐metastases who were treated between January 2007 and
December 2008. For two of these hospitals, the Máxima Medical
Center (MMC) and the Jeroen Bosch Hospital, data from the
years 2000 to 2006 were also available as were data of MMC
from the additional years of 2009 to 2011. The second group
consisted of patients with SLN positive disease from the Gelderse
Vallei Hospital and was used for external validation of the
developed prediction model. The third group of patients were
those found to have the node‐positive disease by UGLNB and
who were treated at the MMC between January 2006 and
December 2011.6 In accordance with Dutch guidelines21 all
patients had sonographic evaluation of the axilla after mammo-
graphy and clinical evaluation. UGLNB (with cytological and/or
histological sampling) was performed on suspicious axillary LNs
as previously described.6 All patients included in the present
study underwent a completion ALND. Patients receiving neo‐
adjuvant treatment, those with stage IV breast cancer and
patients with a clinical N2‐3 axillary status or without a
completion ALND were excluded from the study.
2.2 | Data accrual
Data were collected from an existing database of the NCR and
from the patients’ medical charts and pathology reports. The
following data were collected: age at diagnosis, lateralization of
the tumor, type of surgery, tumor morphology, tumor size (mm),
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histological grade (conform modified Bloom and Richardson
classification), presence of lymphovascular invasion (LVI), multi-
focality, estrogen and progesterone receptor status, and Her2Neu
status. Histopathological data of the LNs included: total number of
resected and positive/negatives nodes for both the SLNB‐
procedure and the ALND, the size of the largest metastases of
the SLN as a continuous variable (in mm) and categorized as
macrometastases (>2 mm), micrometastases (>0.2 but ≤2 mm) or
isolated tumor cells (ITC) (≤0.2 mm) and the presence of extra-
capsular extension in the SLN.
The total number of axillary LNs was computed by adding the
total number of nodes harvested during SLNB to the number of
nodes that were found by ALND. The total number of positive
axillary LNs was divided into three categories: 1 to 2, ≥3, or ≥4
positive LNs. For tumor grade, LVI, hormonal receptor and Her2Neu
status, the size of the SLN metastases, and the presence of
extracapsular extension there were some missing values. When
values for LVI were missing and were not reported in the pathology
report, LVI was assumed to be absent. Other missing values were
imputed 20 times with the mice (multiple imputations with chained
equations) algorithms in R software allowing all observed values to
be analyzed.22,23 The imputation model included all predictors and
the total number of positive axillary LNs. We compared results
without and with the imputation of missing values in a sensitivity
analysis.
2.3 | Predictors and model development
Candidate predictors for axillary lymph node involvement were
included in the analysis based on the literature and previously
reported models. These included the models that predict the risk
of having four or more involved axillary LNs.9-20 We developed a
model to predict the number of positive non‐SLNs, and thus the
total number of positive LNs. We used proportional‐odds‐logistic‐
regression‐analysis to model the association between predictors
and the number of positive non‐SLNs. We checked the propor-
tional‐odds‐assumption graphically for all potential predictors. We
evaluated the strength of each predictor by its univariable odds
ratio, and by its multivariable odds ratio together with its
likelihood ratio χ2 test statistic minus twice the degrees of
freedom. The latter is consistent with Akaikeʼs information
criterion which balances the goodness‐of‐fit of a model with its
complexity, and was also used to select predictors into a final
model.24 The patients in the UGLNB‐group were also analyzed as
described before, because we wanted to provide predictions for all
node‐positive breast cancer patients, regardless of the method of
the detection. However, the analysis showed no additional
predictors that could discriminate between low and high‐risk
patients because the method of detection was the strongest
predictor for extensive nodal involvement. Consequently, we did
not develop a separate model and only the overall probabilities of
having a total of 1 to 2, ≥3, or ≥4 positive LNs were derived from
the present dataset.
2.4 | Presentation of the prediction model
For easy calculation of the probability of having a particular number
of positive LNs, we presented the final model with a score chart
based on the regression coefficients of the final proportional odds
model.24,25 Predictor values were translated into a sum score that
can be used to read the probability of having a total of 1 to 2, ≥3, or
≥4 positive LNs from a Table, given the number of positive SLNs.
2.5 | Validation of the new prediction model
We validated predictions of having ≥3 positive LNs for patients with
<3 positive SLNs within the development data and the external
validation data. We used validation plots to visualize the performance
of the model.26 The ability of our model to predict ≥4 positive LNs was
compared with the previously developed nomograms by Katz et al,
Meretoja et al, and Chagpar et al18-20 We assessed the calibration of
our model by the calibration slope and the calibration‐in‐the‐large.25
We assessed the discriminative ability by the area under the curve
(AUC) of the receiver operating characteristic curve. Since we are
assessing predictions of binary outcomes, the AUC is equal to the
c‐index, which estimates the probability that the risk prediction of a
randomly chosen patient with the outcome is higher than the risk
prediction of a randomly chosen patient without the outcome.
For proportional‐odds‐regression‐analysis and validation of pre-
diction models, we used R package rms (version 2.13.1; R Foundation
for Statistical Computing, Vienna, Austria)
3 | RESULTS
A total of 1230 patients with node‐positive breast cancer were
included in this study. The model development population consisted
of 911 patients, the external validation population of 180 and the
UGLNB‐group of 139 patients. Of the 911 patients from the model
development population, 349 (38%) underwent a mastectomy and
562 (62%) were treated with BCS. For 259 (28%) patients, the final
pathology showed additional positive LNs after completion of ALND.
Of these, 175 (19%) had a total of three or more involved axillary LNs
(Table 1). The observed overall proportions of patients in the
UGLNB‐group with a total of 1 to 2, ≥3, or ≥4 positive LNs were 37%,
63%, and 51%, respectively.
3.1 | Predictors and model development
The univariable analysis showed the following significant predictors
for additional axillary lymph node involvement: tumor size (mm),
tumor grade, LVI, presence of a negative SLN, >1 positive SLN, SLN
macrometastases, an SLN metastases size >5mm, and the presence
of extracapsular extension. Predictor effects of age >65‐year
mulitfocality of the tumor, invasive lobular carcinoma morphology,
a positive ER status, a positive PR status, and a positive Her2Neu
status were nonsignificant but in the expected direction (Table 2).
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TABLE 1 Characteristics of the total study population
Development group External validation group UGLNB group
Variables N % N % N %
Age at diagnosis (y)
≤50 297 32.6 59 32.8 42 30.2
>50 ≤65 363 39.8 68 37.8 38 27.3
>65 251 27.6 53 29.4 59 42.4
Laterality
Left 473 51.9 93 51.7 78 56.1
Right 437 48.0 87 48.3 61 43.9
Missing 1 0.1 0 0 0 0
Type of surgery
BCS 562 61.7 97 53.9 49 35.3
Mastectomy 349 38.3 83 46.1 90 64.7
Tumor size (mm)
≤5 20 2.2 3 1.7 2 1.4
6‐10 72 7.9 12 6.7 3 2.2
11‐20 446 49.0 99 55.0 23 16.5
21‐30 270 29.6 50 27.8 102 73.4
31‐50 90 9.9 14 7.8 9 6.5
>50 13 1.4 2 1.1 0 0
Multifocal
Yes 112 12.3 24 13.3 24 17.3
No 799 87.7 156 86.7 111 79.9
Missing 0 0 0 0 4 2.9
Morphology
IDC 722 79.3 130 72.2 108 72.7
ILC 156 17.1 30 6.7 23 16.5
Other 33 3.6 20 11.1 8 5.8
Tumor grade
1 263 28.8 34 18.9 23 16.5
2 421 46.2 89 49.4 75 54.0
3 155 17.0 52 28.9 38 27.3
Missing 72 7.9 5 2.8 3 2.2
LVI
Yes 179 19.6 26 14.4 34 24.5
No 421 46.2 121 67.2 80 57.6
Missing 311 34.1 33 18.3 25 18.0
ER status
Positive 780 85.6 146 81.1 100 71.9
Negative 114 12.5 34 18.9 39 28.1
Missing 17 1.9 0 0 0 0
PR status
Positive 673 73.9 120 66.7 80 57.6
Negative 183 20.1 60 33.3 59 42.4
Missing 55 6.0 0 0 0 0
Her2Neu status
Positive 80 8.8 24 13.3 26 18.7
Negative 613 67.3 125 69.4 113 81.3
Missing 218 23.9 31 17.2 0 0
SLNs positive
1 755 82.9 152 84.4
2 124 13.6 23 12.8
3 21 2.3 4 2.2
>3 11 1.2 1 0.6
SLN Metastases (mm)
ITC (<0.2) 37 4.1 9 5.0
Micro (0.2‐2.0) 242 26.6 50 27.8
Macro (>2.0) 485 53.2 118 65.6
Missing 147 16.1 3 1.7
(Continues)
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The proportional odds assumption was well satisfied upon
graphical inspection. The effects of the predictors were reasonably
constant across any cut‐off level for the extent of lymph node
positivity (Figure S1, the constant horizontal distance between any
two of the three symbols).
The most important predictors in the multivariable analysis were
(odds ratio [OR] and 95% confidence interval [CI]): tumor size in mm
(OR= 1.04; 95% CI = 1.02‐1.05) the presence of a negative SLN
(OR= 0.48; 95% CI = 0.35‐0.67), the size of the SLN metastases
(in mm) (OR= 1.17; 95% CI = 1.13‐1.22) and the presence of extra-
capsular extension (OR =1.50; 95% CI = 1.01‐2.25) as shown in Table 3.
The regression coefficients in a complete case analysis of the full
model (n = 301) were very similar to the analyses based on imputed
data. Furthermore, none of the other variables were identified as
predictive in the complete case analysis. (Table S1).
3.2 | Presentation of the prediction model
In the final model the following three predictors were selected: the
size of the tumor in mm, the presence of a negative SLN, and the
size of the SLN metastases in mm (Table 3). The model is presented
as a simple score chart (Figure 1). For example, a patient with an
SLN metastasis size of 8 mm, a tumor size of 25 mm, and no
negative SLN has predicted probabilities of 73%, 27%, and 17% of
having a total of 1 to 2, ≥3, or ≥ 4 positive LNs, respectively. The
effect of extracapsular extension appeared to be nonsignificant
after backward selection (P = .12), and the impact of adding ECE to
the model was thus negligible.
3.3 | Validation of the prediction model
The model predictions of having ≥3 positive LNs (for patients with
<3 positive SLNs) were validated within the development data and
the external validation data (Figure 2). In both the apparent and
external validation, the model showed a very good discriminative
ability with AUCs of 0.80 (95% CI = 0.76‐0.84) and 0.82 (95%
CI = 0.74‐0.90), respectively. Calibration was good over the com-
plete range of predicted probabilities in both the apparent and
external validation (Figure 2). When the actual size of the SLN
metastases (in mm) is not provided, assigning eight points for
macrometastases gives a good approximation. The performance of
the model then remained satisfactory with an AUC of 0.79 (95%
CI = 0.75‐0.83) in apparent validation and 0.80 (95% CI = 0.72‐0.88)
at external validation (Figure S2).
3.4 | Comparison with previously developed
models
When predicting the probability of having ≥4 positive LNs (for
patients with less than four positive SLNs), the discriminative ability
of our new model was equally good or even better in the external
validation data (AUC = 0.82; 95% CI = 0.74‐0.90) as compared with
the three previously developed predictive systems (18‐20) (AUCʼs of
0.82, 0.80, and 0.66, respectively). Furthermore, calibration was also
superior for the newly developed prediction model (Figure S3).
4 | DISCUSSION
Early stage breast cancer patients, with limited nodal involvement,
are no longer subjected to a completion ALND, based on the results
of the IBCSG 23‐01, AMAROS, and Z0011 trials.1-3 Because the
evidence for omitting further axillary treatment in patients with
extensive nodal involvement is lacking, it is useful to predict the
extent of nodal involvement.
We have developed a novel model that predicts the risk of having
a total of 1 to 2, ≥3, or ≥4 positive LNs using only three predictors:
tumor size (in mm), the presence of a negative SLN and the size of the
SLN metastases (in mm). Although the presence of extracapsular
extension also showed to be a significant predictor in both
univariable and multivariable analysis we chose to incorporate only
the three strongest predictors. This did not affect model performance
and was in line with the aim of this study to keep the model as simple
and user‐friendly as possible. The discriminative ability of the model
was good (AUC of 0.80) and it showed adequate calibration over the
complete range of predicted probabilities. Furthermore, the model
TABLE 1 (Continued)
Development group External validation group UGLNB group
Variables N % N % N %
Extracapsular extension
Yes 184 20.2 29 16.1
No 650 71.3 86 47.8
Missing 77 8.5 65 36.1
Total number of positive lymph nodes
1‐2 736 80.8 148 82.2 51 36.7
≥3 175 19.2 32 17.8 88 64.0
≥4 111 12.2 24 13.3 71 51.1
Overall 911 180 139
Abbreviations: ITC, isolated tumor cells; LVI, lymphovascular invasion; SLN, sentinel lymph node.
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TABLE 2 Univariable associations between predictors and the number of additional positive lymph nodes
Additional positive lymph nodes % Odds Lower Upper
Predictors Level N ≥1 ≥2 ≥3 ≥1 ≥2 ≥3 Ratio 0.95 0.95
Age at diagnosis ≤50 297 89 51 29 30 17 10 1.00
(y) >50 ≤65 363 104 56 40 29 15 11 0.94 0.68 1.31
>65 251 66 31 18 26 12 7 0.81 0.56 1.17
Laterality (left) No 437 130 70 42 30 016 10 1.00
Yes 473 129 68 45 27 14 10 0.89 0.67 1.18
Mastectomy No 562 157 82 53 28 15 9 1.00
Yes 349 102 56 34 29 16 10 1.07 0.80 1.43
Tumor size (mm) ≤15 327 65 30 19 20 9 6 1.00
<15 ≤25 400 114 48 30 29 12 8 1.56 1.10 2.20
>25 184 80 60 38 43 33 21 3.52 2.38 5.22
Multifocal No 799 223 117 72 28 15 9 1.00
Yes 112 36 21 15 32 19 13 1.26 0.83 1.92
Morphology (ILC) No 755 210 104 65 28 14 9 1.00
Yes 156 49 34 22 31 22 14 1.29 0.89 1.87
Tumor grade 1 263 61 30 21 23 11 8 1.00
2 421 134 73 43 32 17 10 1.54 1.09 2.18
3+ 155 54 30 21 35 19 14 1.84 1.21 2.80
LVI No 732 196 100 60 27 14 8 1.00
Yes 179 63 38 27 35 21 15 1.55 1.10 2.18
ER positive No 114 36 22 14 32 19 12 1.00
Yes 780 223 116 73 29 15 9 0.84 0.55 1.27
PR positive No 183 56 31 21 31 17 11 1.00
Yes 673 194 104 64 29 15 10 0.91 0.64 1.29
Her2Neu positive No 613 158 88 54 26 14 9 1.00
Yes 80 30 14 8 38 18 10 1.60 1.00 2.56
SLNs negative 0 518 179 101 65 35 19 13 1.00
1 260 54 24 16 21 9 6 0.49 0.34 0.69
2+ 133 26 13 6 20 10 5 0.45 0.29 0.72
SLNs positive 1 755 195 96 58 26 13 8 1.00
2+ 156 64 42 29 41 27 19 2.15 1.52 3.05
Macrometastases No 279 36 12 5 13 4 2 1.00
Yes 485 177 102 65 36 21 13 4.05 2.73 6.00
Size of SLN ≤2 218 24 7 3 11 3 1 1.00
metastases (mm) >2 ≤5 183 36 13 9 20 7 5 1.99 1.14 3.47
>5 207 97 58 32 47 28 15 7.56 4.58 12.47
ECE No 651 156 77 47 24 12 7 1.00
Yes 184 85 51 35 46 28 19 2.78 2.00 3.86
Overall 911 259 138 87 0.28 0.15 0.10
Note: Odds ratios are estimated with proportional odds regression analysis.
Abbreviations: ECE, extracapsular extension; ER, estrogen receptor status; ILC, invasive lobular carcinoma; LVI, lymphovascular invasion; PR,
progesterone receptor status; SLN(s), sentinel lymph node(s).
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was validated in an independent external patient population and
showed good discrimination (AUC 0.82) and calibration.
Because we wanted to provide risk predictions for all node‐
positive breast cancer patients, regardless of the method of
detection, also an UGLNB‐group was analyzed. However, when the
lymph node metastases are detected by ultrasound, this staging
method by itself seems to be the most important predictor for
extensive nodal involvement given the fact that 63% of these
patients had ≥3 positive LNs. These findings are in concordance with
the results of Schipper et al27, that showed that the finding of
suspicious nodes with ultrasound resulted in pN2‐pN3 disease in
41.2% of the patients. For this patient group, we found no additional
predictors that could further discriminate between low‐ and high‐risk
patients. Consequently, we decided that the development of a
separate model for this group was not relevant. Because these
patients also need counseling regarding the axillary treatment
strategy, the overall risk estimates of having a total of 1 to 2, ≥3,
or ≥4 positive LNs are also visualized in our prediction tool.
Previously published models were mostly developed before the
publication of the Z0011‐trial results and are intended to identify
patients at low risk for additional nodal involvement for whom a
completion ALND could be omitted.9-14,16,17 The few models that have
been designed to predict the risk of having ≥4 involved LNs were used to
guide decisions on the extent of radiation and systemic therapy
regimens.18-20 To our knowledge our model is the first that actually
predicts the extent of nodal involvement, therefore easily classifying
patients to have limited nodal involvement (1‐2 positive LNs, corre-
sponding to the conclusions of Z0011) or extensive lymph node
involvement (≥3 positive LNs). Although it was not a primary goal of
this study, our model also predicts the risk of having ≥4 positive LNs.
This is another cut‐off‐point for extensive nodal involvement that is used
to decide about the need for additional axillary irradiation. The new
model was compared with the existing three models that predict ≥4
positive LNs and outperformed the other models in terms of
discriminative ability and calibration for our Dutch population.
The variables included in our new prediction tool already proved
to be strongly associated with nodal involvement in other models and
validation studies. Furthermore, other previously reported models
included up to nine variables, resulting in more complex calculations
and a less user‐friendly model.15 The present study shows that model
performance can still be very good when only a few but strongly
prognostic variables are included.
Our study has limitations. A retrospectively collected database
was used that contained some missing values. The size of the SLN
metastases (in mm) is a strong predictor for extensive nodal
involvement, however, the actual size was not always provided.
Although our model also works based on the presence or absence of
a macrometastasis in the SLN, with acceptable model performance,
we recommend that the actual size of the SLN metastases should be
reported consistently by pathologists to enable more accurate
predictions. The risk predictions for patients that were found node
positive by UGLNB are based on relatively small sample size.
Therefore, we are currently investigating whether these risks will
be similar in a larger population.
Some clinicians have already abandoned the use of ALND for SLN
positive patients. However, we must be aware of the generalization of
the conclusions of the Z0011‐trial, as these are only applicable to about
6% of the total breast cancer population.28 An advantage of our new
model is that the online tool can visualize the predicted risk of the extent
of nodal disease for each individual patient. Therefore the model can be
a useful tool in counseling patients, to help them understand their risks.
Because the model gives no actual treatment recommendations, or a
given cut‐off point, the risks and benefits of further axillary treatment
need to be weighed individually. Following the results of the Z0011 and
AMAROS trials, it appears reasonable to give no further axillary
treatment to patients that are very likely to have limited nodal
involvement (1‐2 positive LNs) provided that adjuvant systemic
treatment is offered, and consider radiation therapy of the axilla or a
completion ALND when they are at risk for extensive nodal involvement
( ≥3 positive LNs). We strongly advise against the omission of further
axillary treatment for patients with a high risk of having ≥4 positive LNs.
In conclusion, we have developed and validated a new model that
predicts the extent of nodal involvement in node‐positive breast
cancer patients. This new tool will particularly be useful for
counseling patients regarding their personalized axillary treatment.
TABLE 3 Multivariable associations between predictors and the
number of additional positive lymph nodes, based on a model with all
potential predictors (Full model) and a model with the three
strongest predictors (Selected model)
Odds Lower Upper
χ2 df PPredictors ratio 0.95 0.95
Full model
Age at diagnosis (10 y) 0.94 0.83 1.07 0.8 1 .3638
Laterality (left) 0.96 0.70 1.31 0.1 1 .8057
Mastectomy 0.77 0.55 1.08 2.2 1 .1362
Tumor size (mm) 1.04 1.02 1.05 20.7 1 <.0001
Multifocality 1.18 0.73 1.91 0.5 1 .4947
Morphology (ILC) 1.16 0.75 1.81 0.4 1 .5068
Tumor grade 2:1 1.42 0.96 2.11 4.2 2 .1216
Tumor grade 3:1 1.65 0.98 2.79
LVI 1.14 0.78 1.69 0.5 1 .4946
ER positive 0.92 0.52 1.65 0.1 1 .7883
PR positive 1.09 0.68 1.77 0.1 1 .7128
Her2Neu positive 1.35 0.82 2.23 1.4 1 .2437
SLNs negative 0.47 0.34 0.66 19.3 1 <.0001
SLNs positive 1.41 0.95 2.10 2.9 1 .0899
Size of SLN
metastases (mm)
1.15 1.10 1.21 41.1 1 <.0001
ECE 1.50 1.01 2.25 4.0 1 .0466
Selected model
Tumor size (mm) 1.04 1.02 1.05 26.6 1 <.0001
SLNs negative 0.48 0.35 0.67 19.3 1 <.0001
Size of SLN
metastases (mm)
1.17 1.13 1.22 63.5 1 <.0001
Note: Odds ratios are estimated with proportional odds regression
analysis.
Abbreviations: ECE, extracapsular extension; ER, estrogen receptor
status; ILC, invasive lobular carcinoma; LVI, lymphovascular invasion; PR,
progesterone receptor status; SLN(s), sentinel lymph node(s).
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F IGURE 1 Score chart for the
probability of finding a total of 1 to 2, ≥3,
or ≥4 positive lymph nodes. For example, in
a patient with one positive sentinel lymph
node (SLN) with a largest size of the
metastasis of 8 mm, a tumor size of 25mm,
and no negative SLN found, the score is
calculated as follows: [8] (8 mm largest
metastasis size) + [0.25 × 25] (25mm
tumor size) + [5] (if no negative SLN was
found), which makes a (rounded) sum score
of 19 points. The probabilities can then be
read from the chart on the horizontal line
following the 19 (sum score). The
probability of having only 1 to 2 nodes
positive is 73%, the risk of having ≥3
positive lymph nodes is 27% and the risk of
having ≥4 is 17%. For a similar patients
with a negative SLN the sum score would
be 14: [8] + [0.25 × 25] + 0. And the
corresponding probabilities of having 1 to
2, ≥ 3, or ≥ 4 positive lymph nodes would
be 86%, 14%, and 8.2%, respectively
F IGURE 2 Internal (left) and external (right) validation of the predicted probability of ≥3 positive lymph nodes (when the number of positive
SLNs is <3). The distribution of predicted risks for ≥3 or more positive axillary lymph nodes is shown at the bottom of the graphs. The triangles
indicate the observed proportions by quartiles of predicted risks. SLN, sentinel lymph node
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